高恶性肿瘤变体保留了被辅助性T细胞识别的肿瘤特异性抗原。
Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells.
作者信息
Van Waes C, Urban J L, Rothstein J L, Ward P L, Schreiber H
出版信息
J Exp Med. 1986 Nov 1;164(5):1547-65. doi: 10.1084/jem.164.5.1547.
Abstract
We have studied the components of a complex of tumor-specific antigens to determine if all of the components of the complex were lost during progression from a rather benign regressor tumor to a highly malignant (HM) cancer. We find that the HM tumor cells have lost antigens recognized by CTL but retained antigens recognized by Th cells. Immunization with variants expressing Th-defined antigens induced tumor-specific immunity to challenge with a parental variant that expressed a CTL-recognized target antigen, but did not induce immunity to challenge with the variant that expressed the Th-defined antigen alone. Together, these findings suggested that Th cells fail to exert direct selective pressure upon the tumor, resulting in retention of "lineage-specific," Th-recognized antigens by highly immunoselected variants. Possible advantage could be taken of this fact for the development of specific immunotherapy.
摘要
我们研究了肿瘤特异性抗原复合物的成分，以确定在从相对良性的消退性肿瘤进展为高度恶性（HM）癌症的过程中，该复合物的所有成分是否都会丢失。我们发现，HM肿瘤细胞已失去被细胞毒性T淋巴细胞（CTL）识别的抗原，但保留了被辅助性T细胞（Th细胞）识别的抗原。用表达Th细胞定义抗原的变体进行免疫，可诱导肿瘤特异性免疫，从而抵御表达CTL识别的靶抗原的亲本变体的攻击，但不能诱导抵御仅表达Th细胞定义抗原的变体的攻击。这些发现共同表明，Th细胞未能对肿瘤施加直接的选择压力，导致高度免疫选择的变体保留了“谱系特异性”的、Th细胞识别的抗原。利用这一事实可能有利于开发特异性免疫疗法。
相似文献
1
Highly malignant tumor variants retain tumor-specific antigens recognized by T helper cells.高恶性肿瘤变体保留了被辅助性T细胞识别的肿瘤特异性抗原。
J Exp Med. 1986 Nov 1;164(5):1547-65. doi: 10.1084/jem.164.5.1547.
2
Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.体外和体内测量的紫外线辐射诱导的抗原性肿瘤细胞变体上抗原的特异性。
Cancer Res. 1989 Mar 1;49(5):1207-13.
3
4
Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro.免疫显性会抑制对其他肿瘤抗原的反应，从而有利于肿瘤逃逸：通过在体外使用克隆的细胞溶解T细胞选择的肿瘤变体进行疫苗接种来预防。
Tissue Antigens. 1996 May;47(5):399-407. doi: 10.1111/j.1399-0039.1996.tb02575.x.
5
Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.在体外使用细胞溶解性T细胞系进行变体选择后，正常宿主体内出现恶性生长。
Proc Natl Acad Sci U S A. 1984 Apr;81(7):2186-90. doi: 10.1073/pnas.81.7.2186.
6
The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.病毒辅助增强肿瘤特异性免疫。III. 肿瘤特异性Lyt-1+2- T细胞生成的增强是体内肿瘤免疫增强的原因。
Cancer Immunol Immunother. 1986;21(3):193-8. doi: 10.1007/BF00199361.
7
A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.一种失去了一个主要组织相容性复合体I类限制性元件的肿瘤逃逸变体，会将特异性CD8 + T细胞诱导至一种不再作为靶点的抗原。
J Exp Med. 1993 Sep 1;178(3):933-40. doi: 10.1084/jem.178.3.933.
8
Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.利用牛痘病毒反应性辅助性T细胞活性建立肿瘤特异性免疫治疗模型。
Eur J Immunol. 1988 Nov;18(11):1773-8. doi: 10.1002/eji.1830181118.
9
Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens.通过细胞毒性T淋巴细胞免疫选择从3-甲基胆蒽诱导的小鼠肉瘤中丧失独特肿瘤抗原，揭示了继发性独特抗原和共享抗原。
J Exp Med. 1996 Aug 1;184(2):441-7. doi: 10.1084/jem.184.2.441.
10
Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.细胞毒性T淋巴细胞识别抗原表达降低的肿瘤缺乏免疫原性，但对细胞毒性T淋巴细胞的裂解仍保持敏感性。
Eur J Immunol. 1993 Nov;23(11):2770-6. doi: 10.1002/eji.1830231108.
引用本文的文献
1
Potential and development of cellular vesicle vaccines in cancer immunotherapy.细胞囊泡疫苗在癌症免疫治疗中的潜力与发展
Discov Oncol. 2025 Jan 15;16(1):48. doi: 10.1007/s12672-025-01781-3.
2
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.新辅助 PD-1 免疫检查点阻断逆转肿瘤抗原特异性 T 细胞的功能优势。
Clin Cancer Res. 2020 Feb 1;26(3):679-689. doi: 10.1158/1078-0432.CCR-19-2209. Epub 2019 Oct 23.
3
CD4 and CD8 T lymphocyte interplay in controlling tumor growth.CD4 和 CD8 T 淋巴细胞在控制肿瘤生长中的相互作用。
Cell Mol Life Sci. 2018 Feb;75(4):689-713. doi: 10.1007/s00018-017-2686-7. Epub 2017 Oct 14.
4
Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients.黑色素瘤患者循环肿瘤裂解物反应性CD4 + T细胞的检测
Cancer Immunol Immunother. 2004 Jun;53(6):560-6. doi: 10.1007/s00262-004-0502-3. Epub 2004 Feb 25.
5
Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens.必需基因中的点突变以及第二个等位基因的缺失或突变：与肿瘤特异性抗原保留的相关性。
J Exp Med. 2001 Aug 6;194(3):285-300. doi: 10.1084/jem.194.3.285.
6
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.CD4(+) T细胞通过干扰素-γ的间接作用在体内清除MHC II类阴性癌细胞。
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8633-8. doi: 10.1073/pnas.96.15.8633.
7
Metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction.源自体外转化的鳞状细胞癌系体内肿瘤进展后的转移变体获得了需要肿瘤与宿主相互作用的差异性生长优势。
Clin Exp Metastasis. 1997 Sep;15(5):527-37. doi: 10.1023/a:1018474910432.
8
A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.一种失去了一个主要组织相容性复合体I类限制性元件的肿瘤逃逸变体，会将特异性CD8 + T细胞诱导至一种不再作为靶点的抗原。
J Exp Med. 1993 Sep 1;178(3):933-40. doi: 10.1084/jem.178.3.933.
9
Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer.通过分子克隆和基因转移鉴定独特的肿瘤抗原作为排斥抗原。
J Exp Med. 1986 Nov 1;164(5):1516-30. doi: 10.1084/jem.164.5.1516.
10
Immunogenic capacity of tum--variants isolated from a rat rhabdomyosarcoma.从大鼠横纹肌肉瘤中分离出的肿瘤变体的免疫原性能力。
Br J Cancer. 1987 Jul;56(1):7-13. doi: 10.1038/bjc.1987.144.
本文引用的文献
1
THE PROGRESSION TO CARCINOMA OF VIRUS-INDUCED RABBIT PAPILLOMAS (SHOPE).病毒诱导的兔乳头瘤（绍普）癌的进展
J Exp Med. 1935 Sep 30;62(4):523-48. doi: 10.1084/jem.62.4.523.
2
THE EFFICIENT DESIGN OF TRANSPLANTABLE TUMOUR ASSAYS.可移植肿瘤检测的高效设计
Br J Cancer. 1963 Dec;17(4):583-95. doi: 10.1038/bjc.1963.78.
3
The immune response and the homograft reaction.免疫反应与同种异体移植反应。
Natl Cancer Inst Monogr. 1960 Mar;2:113-38.
4
The experimental study of tumor progression: a review.肿瘤进展的实验研究：综述
Cancer Res. 1954 Jun;14(5):327-39.
5
Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation.用紫外线辐射抑制的小鼠对肿瘤细胞变体的免疫选择
J Exp Med. 1982 Oct 1;156(4):1025-41. doi: 10.1084/jem.156.4.1025.
6
Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.用于确定免疫活性细胞频率的有限稀释分析。I. 数据分析。
J Immunol. 1981 Apr;126(4):1614-9.
7
Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.同基因肿瘤排斥的机制。宿主选择的进展性变体对各种免疫效应细胞的敏感性。
J Exp Med. 1982 Feb 1;155(2):557-73. doi: 10.1084/jem.155.2.557.
8
Enumeration of alloreactive helper T lymphocytes which cooperate with cytolytic T lymphocytes.与细胞溶解性T淋巴细胞协同作用的同种异体反应性辅助性T淋巴细胞的计数。
Eur J Immunol. 1981 Sep;11(9):726-34. doi: 10.1002/eji.1830110911.
9
Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines.在体外使用细胞溶解性T细胞系进行变体选择后，正常宿主体内出现恶性生长。
Proc Natl Acad Sci U S A. 1984 Apr;81(7):2186-90. doi: 10.1073/pnas.81.7.2186.
10
Multiple tumour-specific antigens expressed on a single tumour cell.单个肿瘤细胞上表达多种肿瘤特异性抗原。
Nature. 1983;304(5922):165-7. doi: 10.1038/304165a0.
Zotero 插件